FollowMyHealth Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110
Phone: 314-747-7222

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM
N Engl J Med. 2018 Apr 12; 378(15)1396-1407. doi: 10.1056/NEJMoa1801445.

PMID:
    29641966
    [PubMed - in process]
Related citations


Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR
Blood. 2018 Mar 5; pii: blood-2017-12-821009. doi: 10.1182/blood-2017-12-821009.

PMID:
    29507077
    [PubMed - as supplied by publisher]
Related citations


Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Mehta-Shah N, Bartlett NL
Blood. 2018 Apr 12; 131(15)1698-1703. doi: 10.1182/blood-2017-09-772681.

PMID:
    29500171
    [PubMed - in process]
Related citations


SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP, Fanale MA, Bartlett NL
Clin Lymphoma Myeloma Leuk. 2018 Feb; 18(2)81-90. doi: 10.1016/j.clml.2018.01.001.

PMID:
    29366607
    [PubMed - in process]
Related citations


Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
Blood. 2018 Mar 15; 131(11)1183-1194. doi: 10.1182/blood-2017-10-811224.

PMID:
    29229594
    [PubMed - in process]
Related citations


Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med. 2017 Dec 28; 377(26)2531-2544. doi: 10.1056/NEJMoa1707447.

PMID:
    29226797
    [PubMed - indexed for MEDLINE]
Related citations


Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group.
N Engl J Med. 2018 Jan 25; 378(4)331-344. doi: 10.1056/NEJMoa1708984.

PMID:
    29224502
    [PubMed - indexed for MEDLINE]
Related citations


Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017(1)317-323. doi: 10.1182/asheducation-2017.1.317.

PMID:
    29222273
    [PubMed - in process]
Related citations


Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP
Br J Haematol. 2017 Dec; 179(5)739-747. doi: 10.1111/bjh.14951.

PMID:
    29082519
    [PubMed - indexed for MEDLINE]
Related citations


Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA
Blood. 2018 Jan 11; 131(2)182-190. doi: 10.1182/blood-2017-09-804641.

PMID:
    29074501
    [PubMed - in process]
Related citations


Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A
Blood. 2017 Dec 21; 130(25)2709-2717. doi: 10.1182/blood-2017-05-780049.

PMID:
    28974506
    [PubMed - indexed for MEDLINE]
Related citations


A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD
Ann Oncol. 2017 Nov 1; 28(11)2806-2812. doi: 10.1093/annonc/mdx496.

PMID:
    28945884
    [PubMed - indexed for MEDLINE]
Related citations


Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM
Cancer. 2018 Jan 1; 124(1)136-144. doi: 10.1002/cncr.30979.

PMID:
    28902390
    [PubMed - indexed for MEDLINE]
Related citations


Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, Lim KH
Biol Blood Marrow Transplant. 2017 Dec; 23(12)2199-2204. doi: 10.1016/j.bbmt.2017.08.022.

PMID:
    28847710
    [PubMed - in process]
Related citations


A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
Clin Lymphoma Myeloma Leuk. 2017 Jun; 17(6)347-353. doi: 10.1016/j.clml.2017.05.008.

PMID:
    28622959
    [PubMed - indexed for MEDLINE]
Related citations


Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
Leuk Lymphoma. 2018 Feb; 59(2)357-362. doi: 10.1080/10428194.2017.1330954.

PMID:
    28597723
    [PubMed - in process]
Related citations


Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP
Br J Haematol. 2017 Jul; 178(2)250-256. doi: 10.1111/bjh.14667.

PMID:
    28419413
    [PubMed - indexed for MEDLINE]
Related citations


Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
Lancet Haematol. 2017 Apr; 4(4)e176-e182. doi: 10.1016/S2352-3026(17)30028-5.

PMID:
    28314699
    [PubMed - indexed for MEDLINE]
Related citations


Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY
Mol Ther. 2017 Jan 4; 25(1)285-295. doi: 10.1016/j.ymthe.2016.10.020.

PMID:
    28129122
    [PubMed - indexed for MEDLINE]
Related citations


Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
Blood. 2017 Jan 26; 129(4)473-483. doi: 10.1182/blood-2016-07-729954.

PMID:
    28064239
    [PubMed - indexed for MEDLINE]
Related citations